This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Medical Stocks Lagging DaVita (DVA) This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Avadel (AVDL) have performed compared to their sector so far this year.
Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why You Should Invest in Avadel (AVDL) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
by Zacks Equity Research
The consensus price target hints at a 37.4% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
by Zacks Equity Research
Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.
Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 105.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Do Options Traders Know Something About Avadel (AVDL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.
Implied Volatility Surging for Avadel (AVDL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.
Avadel (AVDL) Surges: Stock Moves 7.8% Higher
by Zacks Equity Research
Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
How Avadel (AVDL) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Avadel (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Avadel (AVDL) Beats on Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Avadel's (AVDL) first quarter 2020 earnings and revenues surpass expectations.
Is a Beat in Store for Avadel (AVDL) This Earnings Season?
by Zacks Equity Research
On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.
Avadel's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.
Is Avadel Pharmaceuticals (AVDL) Stock a Solid Choice Right Now?
by Zacks Equity Research
Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Implied Volatility Surging for Avadel Pharmaceuticals (AVDL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
by Zacks Equity Research
Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
Avadel (AVDL) Is Up 21.13% in One Week: What You Should Know
by Zacks Equity Research
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Top-Ranked ADRs That More Than Doubled the S&P 500 in 2019
by Sanghamitra Saha
Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.